Avibactam/ceftaroline fosamil

Drug Profile

Avibactam/ceftaroline fosamil

Alternative Names: CEF-104; Ceftaroline fosamil/avibactam; Ceftaroline fosamil/NXL 104; CPT-104; CXL; CXL-104; NXL 104/ceftaroline fosamil

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Allergan; AstraZeneca
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Systemic inflammatory response syndrome; Urinary tract infections

Most Recent Events

  • 24 Aug 2016 AstraZeneca plans to sell the commercialisation and development rights to late-stage small molecule antibiotics to Pfizer
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 01 Mar 2014 AstraZeneca completes a phase I pharmacodynamics trial in healthy volunteers in Sweden (NCT01789528)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top